Warfarin

Brand names: Coumadin · Active ingredient: Warfarin Sodium

In short: Warfarin sodium tablets, USP are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.

Forms & strengthsWarfarin Sodium Single-Scored Tablets, USP Strength Color Engraved 1 mg pink 1
LabelRemedyrepack Inc.
Label updatedNov 12, 2026

What is Warfarin used for?

Warfarin sodium tablets, USP are indicated for:

Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).

Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.

Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Limitations of Use

Warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.

âš  Boxed warning (FDA's strongest warning)

Warfarin sodium can cause major or fatal bleeding .

Perform regular monitoring of INR in all treated patients .

Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy .

Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding .

Warfarin dosage

The dosage and administration of warfarin sodium must be individualized for each patient according to the patient's International Normalized Ratio (INR) response to the drug. Adjust the dose based on the patient's INR and the condition being treated. Consult the latest evidence-based clinical practice guidelines regarding the duration and intensity of anticoagulation for the indicated conditions.

An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding.

Venous Thromboembolism (including deep venous thrombosis [DVT] and PE)

Adjust the warfarin dose to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations. The duration of treatment is based on the indication as follows:

For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended.

For patients with an unprovoked DVT or PE, treatment with warfarin is recommended for at least 3 months. After 3 months of therapy, evaluate the risk-benefit ratio of long-term treatment for the individual patient.

For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended. For a patient receiving long-term anticoagulant treatment, periodically reassess the risk-benefit ratio of continuing such treatment in the individual patient.

Atrial Fibrillation

In patients with non-valvular AF, anticoagulate with warfarin to target INR of 2.5 (range, 2.0 to 3.0).

In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke (i.e., having any of the following features: prior ischemic stroke, transient ischemic attack, or systemic embolism, or 2 of the following risk factors: age greater than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.

In patients with non-valvular AF that is persistent or paroxysmal and at an intermediate risk of ischemic stroke (i.e., having 1 of the following risk factors: age greater than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.

For patients with AF and mitral stenosis, long-term anticoagulation with warfarin is recommended.

For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR may be increased and aspirin added depending on valve type and position, and on patient factors. …

How to take Warfarin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Repackaged By / Distributed By: RemedyRepack Inc.

625 Kolter Drive, Indiana, PA 15701

(724) 465-8762

Instructions for Patients

Advise patients to:

Strictly adhere to the prescribed dosage schedule .

If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose of warfarin sodium the next day to make up for missed doses .

Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy .

Be aware that if therapy with warfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about 2 to 5 days .

Avoid any activity or sport that may result in traumatic injury . And to tell their physician if they fall often as this may increase their risk for complications.

Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid drastic changes in dietary habits, such as eating large amounts of leafy, green vegetables .

Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever . …

Warnings & precautions

Do not take this medicine if: Warfarin sodium tablets, USP are contraindicated in:

Pregnancy

Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus .

Warfarin sodium tablets, USP are contraindicated in patients with:

Hemorrhagic tendencies or blood dyscrasias

Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces

Bleeding tendencies associated with:

Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract

Central nervous system hemorrhage

Cerebral aneurysms, dissecting aorta

Pericarditis and pericardial effusions

Bacterial endocarditis

Threatened abortion, eclampsia, and preeclampsia

Unsupervised patients with conditions associated with potential high level of non-compliance

Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding

Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis)

Major regional or lumbar block anesthesia

Malignant hypertension

Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. …

Warfarin side effects

The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling:

Hemorrhage

Tissue Necrosis

Calciphylaxis

Acute Kidney Injury

Systemic Atheroemboli and Cholesterol Microemboli

Limb Ischemia, Necrosis, and Gangrene in Patients with HIT and HITTS

Other Clinical Settings with Increased Risks

Other adverse reactions to warfarin sodium include:

Immune system disorders: hypersensitivity/allergic reactions (including urticaria and anaphylactic reactions)

Vascular disorders: vasculitis

Hepatobiliary disorders: hepatitis, elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and ticlopidine.

Gastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating

Skin disorders: rash, dermatitis (including bullous eruptions), pruritus, alopecia

Respiratory disorders: tracheal or tracheobronchial calcification

General disorders: chills

Drug interactions

Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) .

Consult the labeling of all concurrently used drugs to obtain further information about interactions with warfarin sodium or adverse reactions pertaining to bleeding.

CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent warfarin

S-enantiomer is metabolized by CYP2C9 while the

R-enantiomer is metabolized by CYP1A2 and 3A4. …

About this medicine

Warfarin sodium tablets contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. The chemical name of warfarin sodium is 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt, which is a racemic mixture of the

R- and

S-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. Its empirical formula is C

19H

15NaO

4, and its structural formula is represented by the following:

Crystalline warfarin sodium occurs as a white, odorless, crystalline powder that is discolored by light. It is very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and ether.

Warfarin sodium tablets, USP for oral use also contain:

All strengths: Anhydrous lactose, corn starch, and magnesium stearate

1 mg: | D&C Red No. 6 Barium Lake

2 mg: | FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake

2.5 mg: | D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake

3 mg: | D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake

4 mg: | FD&C Blue No. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 73b8e5ab-86f8-44f8-b290-346acb81c9ae. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol